· For research use only. Not for human consumption.
For research use only. Not for human consumption.
AOD 9604 has an unusual origin — it’s a fragment of a much larger hormone, and it was originally developed by Monash University in Australia. That background alone makes it stand out in peptide research circles. Most synthetic peptides are built from scratch. This one was essentially carved out of something the body already makes.
If you’ve come across the name and found yourself wondering what it actually is, you’re not alone. The science around peptide fragments can feel abstract fast. This guide cuts through that. We’ll look at what AOD 9604 is, why researchers find it interesting, what preclinical studies have observed, and what quality means when you’re sourcing it for laboratory work.
No hype. No medical claims. Just a plain-English look at a genuinely interesting compound.
TL;DR: AOD 9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal segment known as hGH176-191. It was originally developed at Monash University in Australia and has been investigated in preclinical animal models since the late 1990s. What researchers find particularly notable is that, in animal studies, it did not appear to affect IGF-1 levels or blood glucose — unlike full growth hormone. It is sold for research use only, not for human consumption.
What Is AOD 9604?
AOD 9604 is a synthetic peptide fragment derived from human growth hormone (hGH). Specifically, it corresponds to amino acids 176 through 191 at the C-terminal end of the hGH molecule — which is why it’s sometimes written as hGH176-191 in the research literature. A 2001 study published in The American Journal of Physiology — Endocrinology and Metabolism by Heffernan, Jiang, Thorburn, and colleagues was among the first to characterize its biological activity in animal models. ([Heffernan MA et al., American Journal of Physiology — Endocrinology and Metabolism](https://pubmed.ncbi.nlm.nih.gov/11701440/), 2001)
Think of it this way. Human growth hormone is a long, complex protein made of 191 amino acids. AOD 9604 is the last 16 of those. Researchers at Monash University isolated that stretch because they suspected it carried specific biological activity on its own — separate from the rest of the hormone. That hunch became the starting point for over two decades of preclinical investigation.
The “AOD” in the name stands for Anti-Obesity Drug — a label from the compound’s early development history, not a description of what it does in humans. That clinical framing has no bearing on its current status. AOD 9604 is an experimental research compound with no FDA-approved applications.
AOD 9604 is a synthetic 16-amino-acid fragment derived from the C-terminal region of human growth hormone, corresponding to positions 176 through 191 (hGH176-191). It was first characterized in animal models by Heffernan, Jiang, Thorburn, and colleagues in The American Journal of Physiology — Endocrinology and Metabolism (2001), where researchers documented its in vivo behavior in obese rodent models without the metabolic side effects associated with intact growth hormone. (PMID: 11701440)
What Makes AOD 9604 Unique in Research?
The characteristic that generates the most scientific interest is what AOD 9604 did not appear to do in animal studies. A 2001 study in The American Journal of Physiology found that, in rodent models, the fragment did not elevate IGF-1 (insulin-like growth factor 1) levels or affect blood glucose — two effects commonly associated with full-length human growth hormone. ([Heffernan MA et al., American Journal of Physiology — Endocrinology and Metabolism](https://pubmed.ncbi.nlm.nih.gov/11701440/), 2001)
Why does that matter in research? When scientists study a compound isolated from a larger molecule, they’re partly asking: does this fragment retain the parent molecule’s activity, or does it behave differently? With AOD 9604, the answer appears to be “differently” — at least in preclinical models. That selectivity makes it a useful tool for studying specific biological mechanisms in isolation.
Full growth hormone triggers a wide range of downstream effects in animal models. It raises IGF-1, which stimulates growth across many tissue types. It can affect blood sugar regulation. Researchers interested in studying particular aspects of growth hormone biology have to account for all of that noise. A fragment that appears to act more narrowly gives scientists a cleaner instrument for certain types of investigation.
The selectivity profile of AOD 9604 in preclinical models — active in some biological contexts, apparently inactive in others — is what distinguishes it from full-length hGH as a research compound. It’s not about potency. It’s about specificity, and specificity is what makes a compound useful in experimental design.
What Has Research Found About AOD 9604?
Preclinical research on AOD 9604 has focused primarily on its behavior in rodent and animal models. A 2006 study in the journal Obesity Research by Ng, Liu, Chow, Mukherjee, and colleagues examined the compound’s effects in obese rodents and reported observations related to adipose tissue metabolism in those animal models. ([Ng FM et al., Obesity Research](https://pubmed.ncbi.nlm.nih.gov/16449519/), 2006)
It’s worth being precise about what that means. Researchers observed changes in fat cell behavior in animal models under controlled laboratory conditions. That’s scientifically interesting. It does not mean AOD 9604 has been shown to do anything in humans, and it does not mean conclusions carry over from rodent models automatically.
Here’s a plain-English summary of what the preclinical research has explored:
Fat Cell Metabolism in Animal Models
Several studies in rodent models investigated how AOD 9604 interacted with adipose (fat) tissue. Researchers observed changes in lipid metabolism — specifically, processes related to how fat cells store and release fatty acids. The proposed mechanism involves beta-3 adrenergic receptor activation, a signaling pathway that fat cells use to respond to certain hormonal cues.
Body Composition Observations in Rodents
Some preclinical studies monitored body composition in obese rodent models over time while administering AOD 9604. Researchers documented changes in fat mass relative to controls. These findings were reported in animal model contexts only — they do not constitute evidence of efficacy or safety in humans.
Cartilage and Joint Tissue Research
A smaller body of preclinical work has examined AOD 9604 in models of cartilage and joint tissue. This is a less developed area of the research compared to the metabolic studies, but it has attracted enough interest to appear in the published literature. Researchers in this space are investigating the compound’s possible interactions with growth-related signaling pathways in connective tissue.
A 2006 study in Obesity Research by Ng, Liu, Chow, Mukherjee, and colleagues examined AOD 9604 administration in obese rodent models and reported observations related to adipose tissue metabolism. The researchers noted changes consistent with beta-3 adrenergic receptor-mediated lipolysis in animal subjects, without the IGF-1 elevation associated with intact human growth hormone. (PMID: 16449519)
How AOD 9604 Differs From Growth Hormone
Researchers consistently draw a clear distinction between AOD 9604 and full-length human growth hormone in the literature. A 2001 paper by Heffernan and colleagues in The American Journal of Physiology specifically compared the two, noting that intact hGH produced measurable IGF-1 elevation and glucose effects in animal models, while the isolated 176-191 fragment did not. ([Heffernan MA et al., American Journal of Physiology — Endocrinology and Metabolism](https://pubmed.ncbi.nlm.nih.gov/11701440/), 2001)
That distinction is not minor. IGF-1 drives growth across a wide range of cell types, and its elevation has significant implications in research models. A compound that doesn’t trigger that elevation behaves very differently from the parent hormone — even if it shares 16 amino acids with it.
Here’s a side-by-side look at what the research literature describes for each:
Full-Length Human Growth Hormone (hGH)
A 191-amino-acid protein produced by the pituitary gland. In animal models, it stimulates IGF-1 release, promotes growth in multiple tissue types, and has measurable effects on blood glucose regulation. It’s been extensively studied in both preclinical and clinical settings and has established FDA-approved pharmaceutical applications.
AOD 9604 (hGH176-191)
A 16-amino-acid synthetic fragment of hGH. In preclinical animal models, researchers have not observed the IGF-1 elevation or blood glucose effects seen with full growth hormone. Its research profile is narrower. It has no FDA-approved applications and is studied exclusively in preclinical laboratory contexts.
Researchers and suppliers in this space consistently find that AOD 9604 attracts significant interest precisely because of this contrast with full hGH. The ability to study a subset of growth hormone biology without triggering the full hormonal cascade is genuinely useful from an experimental design standpoint.
Research-Grade AOD 9604: What Quality Means
For any peptide research application, the quality of the compound directly affects the reliability of the results. A 2006 paper in Obesity Research (Ng et al., PMID: 16449519) attributed the metabolic observations in animal models specifically to the AOD 9604 sequence — which means impurities, degraded peptide, or sequence errors would compromise any attempt to replicate those findings. The certificate of analysis (COA) is the document that tells you exactly what you’re working with.
Here’s what to look for when evaluating a COA for AOD 9604:
HPLC Purity
High-performance liquid chromatography (HPLC) purity measures how much of the sample is the actual AOD 9604 compound versus everything else in the vial. Research-grade peptides should show purity above 98%. A lower purity figure means a meaningful portion of your sample is unknown material — which can confound any experimental result.
Mass Spectrometry Confirmation
A reliable COA includes mass spectrometry (MS) data confirming that the compound’s molecular weight matches the expected value for the hGH176-191 sequence. This confirms you have the right peptide — not just a pure sample of something else entirely.
Third-Party Testing
The most trustworthy COAs come from independent, third-party laboratories rather than in-house testing performed by the supplier. Third-party verification removes the supplier’s conflict of interest from the quality confirmation step.
You can review all COAs for Alpha Peptides’ AOD 9604 on our Certificates of Analysis page. Our AOD 9604 product page includes full purity specifications and available vial sizes for research use.
Alpha Peptides provides third-party HPLC and mass spectrometry COAs for AOD 9604, with purity verified above 98% — consistent with the standards referenced in published preclinical research on the compound.
Frequently Asked Questions About AOD 9604
Is AOD 9604 related to HGH?
Yes — directly. AOD 9604 is a synthetic version of the C-terminal fragment of human growth hormone, specifically amino acids 176 through 191. It shares that 16-amino-acid sequence with full-length hGH, but it is a separate compound with a distinct research profile. In preclinical animal models, it has not produced the IGF-1 or blood glucose effects associated with intact growth hormone. ([Heffernan MA et al., American Journal of Physiology, 2001, PMID: 11701440])
Has AOD 9604 been in clinical trials?
Yes — AOD 9604 has a more developed clinical history than many research peptides. It completed Phase II and Phase IIb human clinical trials in Australia and the United States in the early 2000s, sponsored in part by Metabolic Pharmaceuticals. Those trials investigated its behavior in human subjects. However, it has not received FDA approval as a drug for any application, and it is currently available only as a research compound, not for therapeutic or personal use.
What is AOD 9604 made of?
AOD 9604 is a synthetic peptide composed of 16 amino acids that correspond to positions 176 through 191 at the C-terminal end of human growth hormone. It is produced through solid-phase peptide synthesis — a standard laboratory technique for building peptide chains in a controlled sequence. The finished compound is typically supplied as a lyophilized (freeze-dried) powder for research applications.
Where can researchers source AOD 9604?
Research-grade AOD 9604 should come from suppliers who provide full third-party COAs, including HPLC purity data above 98% and mass spectrometry confirmation of the correct molecular weight. Alpha Peptides carries research-grade AOD 9604 tested by independent laboratories. Always review the COA before using any peptide in a research context — ours are available at alpha-peptides.com/coas/.
What Makes AOD 9604 Worth Following in Research?
AOD 9604 sits in an unusual position in the peptide research landscape. It has a documented origin at a major research university, a published preclinical track record going back to the late 1990s, and the distinction of having advanced further into human clinical testing than most research peptides ever do. That’s a credible scientific history — even if it hasn’t translated to an approved clinical application.
What keeps researchers interested is the selectivity question. Why does a fragment of growth hormone appear to interact with some biological systems while leaving others untouched? That’s not a simple question, and the answer could have meaningful implications for how scientists think about growth hormone biology more broadly.
If you’re a researcher sourcing AOD 9604 for laboratory use, start with the COA. Purity and sequence confirmation matter more than anything else when you’re trying to generate reliable preclinical data. The science is only as good as the compound you’re working with.
Explore related peptide research: What Is BPC-157? A Beginner’s Guide to the Body Protection Compound
For research use only. Not for human consumption. AOD 9604 is an experimental compound with no FDA-approved therapeutic applications. All information on this page is provided for educational purposes relating to laboratory and preclinical research. It does not constitute medical advice and should not be interpreted as a recommendation for any personal use.
